ENETS is the European Neuroendocrine Tumor Society
Its aims include:
Improving the diagnosis and therapy of patients with neuroendocrine tumors in an international, interdisciplinary and scientific context the coordination of research at European hospitals and health research institutes, with emphasis on basic and clinical research for the diagnosis and treatment of NETs the education and training of physicians and scientists via annual scientific and educational meetings communicating with and informing patients and patient self-help groups cooperating with the pharmaceutical industry for the development of new diagnostic, therapeutic and information technologies the updating of treatment and standards of care guidelines which are to be made public through conferences and the ENETS website establishment of a European database of gastroenteropancreatic neuroendocrine tumors
Society members, currently numbering nearly 600, bring a variety of expertise from such fields as oncology, pathology, radiology, nuclear medicine, endocrinology, surgery and gastroenterology, to ENETS.
ENETS has gradually attracted members from throughout Europe, and has expanded into the new EU member states, Russia, Australia, South America, Canada, China, India, and the U.S. At the same time, the Society has formed valuable relationships within the pharmaceutical industry, namely with Novartis Pharma AG in Basel, Switzerland, and IPSEN Biotech in Paris.
ENETS cooperates as well with the German Neuroendocrine Tumor Network (NET-WORKs), UKI-NETs, and similar organizations in most member countries. Furthermore, ENETS has launched a number of international and multi-centered clinical trials.